[The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia].
Schneider-Helmert. D D; Hermann. E E; Schoenenberger. G A GA
Key Findings
- One week of DSIP treatment advanced the patient’s sleep phase by about 5 hours.
- The patient was able to quit flunitrazepam abruptly without withdrawal symptoms.
- A normal sleep pattern was maintained for at least one week after the DSIP course.
Practical Outcomes
- DSIP may be a short‑term tool to reset a delayed sleep phase and help with benzodiazepine taper, but the evidence is limited to a single case. Enthusiasts should treat it as experimental, use medical supervision, and be aware that optimal dosing and safety data are not established.
Summary
A 47‑year‑old woman with chronic delayed‑sleep insomnia and low‑dose benzodiazepine dependence was given delta sleep‑inducing peptide (DSIP) for a week in a hospital setting. After treatment her main sleep time moved five hours earlier, she stopped taking flunitrazepam abruptly, and her sleep stayed normal for at least a week after stopping DSIP.
Abstract
A 47-year old woman patient suffering from chronic delayed sleep phase insomnia and low-dose benzodiazepine dependence was treated as an inpatient under close polygraphic control using DSIP (delta sleep inducing peptide) on an intensive-care basis for one week. This treatment resulted in advancing the main sleep phase by 5 hours, in an abrupt and complete withdrawal of flunitrazepam and restitution of a normal sleep profile. Actographic control during an after treatment week confirmed that the success was maintained.
Study Information
pubmed
1987
1987-06-05T00:00:00.000Z
10.1055/s-2008-1068167